Literature DB >> 15292462

N-glucuronidation of carbamazepine in human tissues is mediated by UGT2B7.

Adam G Staines1, Michael W H Coughtrie, Brian Burchell.   

Abstract

Carbamazepine (CBZ) is one of the most widely prescribed anticonvulsants despite a high incidence of idiosyncratic side effects. Metabolism of CBZ is complex, and of the more than 30 metabolites identified, one of the most abundant is CBZ N-glucuronide. To date the uridine diphosphate glucuronosyltransferase (UGT) isoform responsible for the N-glucuronidation of CBZ has not been identified. We have developed a sensitive liquid chromatography/mass spectrometry assay to quantify CBZ glucuronidation, and we report that CBZ is specifically glucuronidated by human UGT2B7. Kinetics of CBZ glucuronidation in human liver, kidney, and intestine microsomes were consistent with those of recombinant UGT2B7, which displayed a Km value of 214 microM and Vmax value of 0.79 pmol/mg/min. In addition to revealing the isoform responsible for CBZ glucuronidation, this is the first example of primary amine glucuronidation by UGT2B7.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15292462     DOI: 10.1124/jpet.104.073114

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

1.  Data Mining FAERS to Analyze Molecular Targets of Drugs Highly Associated with Stevens-Johnson Syndrome.

Authors:  Keith K Burkhart; Darrell Abernethy; David Jackson
Journal:  J Med Toxicol       Date:  2015-06

2.  PharmGKB summary: carbamazepine pathway.

Authors:  Caroline F Thorn; Susan G Leckband; John Kelsoe; J Steven Leeder; Daniel J Müller; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-12       Impact factor: 2.089

3.  Effect of probenecid on the pharmacokinetics of carbamazepine in healthy subjects.

Authors:  Kyoung-Ah Kim; Sae Ock Oh; Pil-Whan Park; Ji-Young Park
Journal:  Eur J Clin Pharmacol       Date:  2005-05-25       Impact factor: 2.953

4.  Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy.

Authors:  Yogita Ghodke Puranik; Angela K Birnbaum; Susan E Marino; Ghada Ahmed; James C Cloyd; Rory P Remmel; Ilo E Leppik; Jatinder K Lamba
Journal:  Pharmacogenomics       Date:  2013-01       Impact factor: 2.533

5.  Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance.

Authors:  Helen E Cubitt; J Brian Houston; Aleksandra Galetin
Journal:  Pharm Res       Date:  2009-01-31       Impact factor: 4.200

Review 6.  Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT).

Authors:  Kathleen M Knights; Andrew Rowland; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

Review 7.  The ABCB1, ABCC2 and RALBP1 polymorphisms are associated with carbamazepine response in epileptic patient: a systematic review.

Authors:  Wefa Boughrara; Amina Chentouf
Journal:  Acta Neurol Belg       Date:  2022-03-24       Impact factor: 2.471

8.  Expression pattern of human ATP-binding cassette transporters in skin.

Authors:  Saya Takenaka; Tomoo Itoh; Ryoichi Fujiwara
Journal:  Pharmacol Res Perspect       Date:  2013-09-08

Review 9.  Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy.

Authors:  Junji Saruwatari; Takateru Ishitsu; Kazuko Nakagawa
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-20

10.  Evaluation of clinical and genetic factors in the population pharmacokinetics of carbamazepine.

Authors:  Vincent L M Yip; Henry Pertinez; Xiaoli Meng; James L Maggs; Daniel F Carr; B Kevin Park; Anthony G Marson; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2020-12-14       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.